Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.51 |
| ▸ | HPGDS | O60760 | 2/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23250002 | 0.89 | CRBN (0.52) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL29692632 | 0.86 | CRBN (0.48) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL21997044 | 0.86 | CRBN (0.48) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL31043982 | 0.85 | CRBN (0.58) | CRBNDDB1HPGDSTMEM97SIGMAR1 | |
| SCHEMBL29927420 | 0.83 | CRBN (0.48) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL29132129 | 0.83 | CRBN (0.48) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL30136008 | 0.81 | CRBN (0.46) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL30066511 | 0.80 | CRBN (0.54) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL24820815 | 0.80 | CRBN (0.58) | CRBNDDB1HPGDSIKZF3TNF | |
| SCHEMBL31547311 | 0.80 | CRBN (0.64) | CRBNDDB1HPGDSIKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA INC. (KR) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | STUB1, AURKA, XIAP | CRBN 757/4885DDB1 377/4885HPGDS 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.